Role of Metoprolol Succinate in the Treatment of Heart Failure
and Atrial Fibrillation: A Systematic Review

J 2020

Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review

VINEREANU, Dragos, Jindřich ŠPINAR, Atul PATHAK a Dariusz KOZLOWSKI

Základní údaje

Originální název

Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review

Autoři

VINEREANU, Dragos (642 Rumunsko, garant), Jindřich ŠPINAR (203 Česká republika, domácí), Atul PATHAK (250 Francie) a Dariusz KOZLOWSKI (616 Polsko)

Vydání

AMERICAN JOURNAL OF THERAPEUTICS, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2020, 1075-2765

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.688

Kód RIV

RIV/00216224:14110/20:00116024

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1097/MJT.0000000000001043

UT WoS

000524232900007

Klíčová slova anglicky

metoprolol; beta-blockers; heart failure; atrial fibrillation

Štítky

14110211, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 7. 2020 09:34, Mgr. Tereza Miškechová

Anotace

V originále

Background: Beta-blockers are one of the most important classes of cardiovascular agents and have been considered a cornerstone therapy in heart diseases, such as heart failure (HF) and atrial fibrillation (AF). Among different beta-blockers, metoprolol is a selective beta(1)-adrenergic antagonist, which has been extensively used since the 1970s. Areas of Uncertainty: Although current guidelines include recommendations for the use of controlled-release metoprolol succinate in specific HF and AF indications, and despite extensive clinical experience with metoprolol, comparative evidence on the use of metoprolol succinate compared with other beta-blockers in these indications is limited. Data Sources: We systematically reviewed the data from head-to-head studies directly comparing this compound with other beta-blockers in the treatment of HF or AF. Only clinical trials and observational studies were considered; no other limits were applied. The quality and relevance of retrieved articles were reviewed. Results: A total of 18 articles of the 353 articles identified were selected for inclusion; 12 HF articles and 6 for AF. Additional references were identified from the bibliographies of retrieved articles. The studies show that oral prophylaxis with an appropriate dose of metoprolol may reduce new incidents of AF in high-risk patients. Furthermore, metoprolol succinate is associated with significant mortality and morbidity benefits in the treatment of HF. Conclusions: Despite the introduction of newer beta-blockers with differing clinical characteristics since its introduction, metoprolol succinate remains a useful drug in both HF and AF.

Citovat

VINEREANU, Dragos, Jindřich ŠPINAR, Atul PATHAK a Dariusz KOZLOWSKI. Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review. AMERICAN JOURNAL OF THERAPEUTICS. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2020, roč. 27, č. 2, s. "E183"-"E193", 11 s. ISSN 1075-2765. Dostupné z: https://dx.doi.org/10.1097/MJT.0000000000001043.

@article{1670606,
   author = {Vinereanu, Dragos and Špinar, Jindřich and Pathak, Atul and Kozlowski, Dariusz},
   article_location = {PHILADELPHIA},
   article_number = {2},
   doi = {http://dx.doi.org/10.1097/MJT.0000000000001043},
   keywords = {metoprolol; beta-blockers; heart failure; atrial fibrillation},
   language = {eng},
   issn = {1075-2765},
   journal = {AMERICAN JOURNAL OF THERAPEUTICS},
   title = {Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review},
   url = {https://journals.lww.com/americantherapeutics/Abstract/2020/03000/Role_of_Metoprolol_Succinate_in_the_Treatment_of.7.aspx},
   volume = {27},
   year = {2020}
}

TY  - JOUR
ID  - 1670606
AU  - Vinereanu, Dragos - Špinar, Jindřich - Pathak, Atul - Kozlowski, Dariusz
PY  - 2020
TI  - Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review
JF  - AMERICAN JOURNAL OF THERAPEUTICS
VL  - 27
IS  - 2
SP  - "E183"-"E193"
EP  - "E183"-"E193"
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 10752765
KW  - metoprolol
KW  - beta-blockers
KW  - heart failure
KW  - atrial fibrillation
UR  - https://journals.lww.com/americantherapeutics/Abstract/2020/03000/Role_of_Metoprolol_Succinate_in_the_Treatment_of.7.aspx
L2  - https://journals.lww.com/americantherapeutics/Abstract/2020/03000/Role_of_Metoprolol_Succinate_in_the_Treatment_of.7.aspx
N2  - Background: Beta-blockers are one of the most important classes of cardiovascular agents and have been considered a cornerstone therapy in heart diseases, such as heart failure (HF) and atrial fibrillation (AF). Among different beta-blockers, metoprolol is a selective beta(1)-adrenergic antagonist, which has been extensively used since the 1970s. Areas of Uncertainty: Although current guidelines include recommendations for the use of controlled-release metoprolol succinate in specific HF and AF indications, and despite extensive clinical experience with metoprolol, comparative evidence on the use of metoprolol succinate compared with other beta-blockers in these indications is limited. Data Sources: We systematically reviewed the data from head-to-head studies directly comparing this compound with other beta-blockers in the treatment of HF or AF. Only clinical trials and observational studies were considered; no other limits were applied. The quality and relevance of retrieved articles were reviewed. Results: A total of 18 articles of the 353 articles identified were selected for inclusion; 12 HF articles and 6 for AF. Additional references were identified from the bibliographies of retrieved articles. The studies show that oral prophylaxis with an appropriate dose of metoprolol may reduce new incidents of AF in high-risk patients. Furthermore, metoprolol succinate is associated with significant mortality and morbidity benefits in the treatment of HF. Conclusions: Despite the introduction of newer beta-blockers with differing clinical characteristics since its introduction, metoprolol succinate remains a useful drug in both HF and AF.
ER  -

VINEREANU, Dragos, Jindřich ŠPINAR, Atul PATHAK a Dariusz KOZLOWSKI. Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review. \textit{AMERICAN JOURNAL OF THERAPEUTICS}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{} WILKINS, 2020, roč.~27, č.~2, s.~''E183''-''E193'', 11 s. ISSN~1075-2765. Dostupné z: https://dx.doi.org/10.1097/MJT.0000000000001043.

Podrobný výpis o publikaci